Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage

Clinical Nephrology

Volumn 72, Issue 6, 2009, Pages 449-456

  Bomback, A S ^a,d   Muskata, P ^b   Bald, E ^c   Chwatko, G ^b   Nowicki, M ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

Aldosterone escape; Aldosterone system; Angiotensin; Hypertension; Obesity; Renin; Spironolactone

Indexed keywords

ALBUMIN; ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; SODIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; ALBUMIN URINE LEVEL; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; MONOTHERAPY; NOCTURNAL BLOOD PRESSURE; OBESITY; POTASSIUM BLOOD LEVEL; TREATMENT DURATION; URINARY EXCRETION;

EID: 71449110620     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72449     Document Type: Article

References (50)

1. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with Type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001; 134: 370-379.
2. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000; 160: 685-693.
3. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70: 2116-2123.
4. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C, Burnier M. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006; 48: 239-245.
5. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007; 3: 486-492.
6. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008; 51: 199-211.
7. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005; 366: 2026-2033.
8. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007; 49: 839-845.
9. Chrysostomou A, Pedagogos E, MacGregor A, Becker GJ. Double-blind, placebo-controlled study on the effect of aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006; 1: 256-262.
10. Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zeni P, Caruso B, Zardini P. Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2002; 89: 403-407.
11. Cuspidi C, Michev I, Meani S, Severgnini B, Fusi V, Corti C et al. Reduced nocturnal fall in blood pressure assessed by two ambulatory blood pressure monitorings and cardiac alterations in early phases of untreated essential hypertension. J Hum Hypertens. 2003; 17: 245-251.
12. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E et al. Is the nocturnal fall in blood pressure reduced in essential hypertensive patients with metabolic syndrome? Blood Press. 2004a; 13: 230-235.
13. Cuspidi C, Meani S, Salerno M, Valerio C, Fusi V, Severgnini B et al. Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure. J Hypertens. 2004b; 22: 273-280.
14. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004; 43: 41-47.
15. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis. 2001; 37 : 677-688.
16. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006; 119: 912-919.
17. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res. 1994; 28: 1863-1867.
18. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res. 1998; 24: 789-796.
19. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996; 98: 1063-1068.
20. Hassan MO, Jaju D, Albarwani S, Al-Yahyaee S, Al-Hadabi S, Lopez-Alvarenga JC et al. Non-dipping blood pressure in the metabolic syndrome among Arabs of the Omanfamily study. Obesity (Silver Spring). 2007; 15: 2445-2453.
21. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult, Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 2001; 104: 2996-3007.
22. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003; 361: 1843-1848.
23. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351: 543-551.
24. K/DOQI Clinical Practice Guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43: S1-S290.
25. Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension. 2008; 51: 1252-1258.
26. Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep. 2003; 5: 408-417.
27. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail. 1999; 1: 401-406.
28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
29. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329: 1456-1462.
30. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med. 2001; 345: 851-860.
31. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999; 82: 57-61.
32. Morales E, Huerta A, Gutierrez-Solis E, Gutierrez E, Polanco N, Gutierrez-Millet V, Gonzalez E, Praga M. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients.Which is themost effective option? J Am Soc Nephrol. 2008; 19: 549A.
33. Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol. 2008; 12: 233-242.
34. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension. 2007; 50: 877-883.
35. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006; 17: 3438-3446.
36. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003; 16: 925-930.
37. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States 1999-2004. JAMA. 2006; 295: 1549-1555.
38. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004; 351: 585-592.
39. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-717.
40. Prakash ES. "Aldosterone escape" or refractory hyperaldosteronism? Med Gen Med. 2005; 7: 25.
41. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998; 158: 26-32.
42. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999; 33: 232-237.
43. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000; 141: 3871-3878.
44. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004; 47: 1936-1939.
45. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail. 2004; 6: 539-545.
46. Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL, Fowler MB. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol. 2002; 39: 70-78.
47. Tartan Z, Uyarel H, Kasikcioglu H, Alper AT, Ozay B, Bilsel T et al. Metabolic syndrome as a predictor of non-dipping hypertension. Tohoku J Exp Med. 2006; 210: 57-66.
48. van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F. Spironolactone in Type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006; 24: 2285-2292.
49. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004; 351: 33-41.
50. Vyssoulis GP, Karpanou EA, Kyvelou SM, Adamopoulos DN, Deligeorgis AD, Spanos PG et al. Nocturnal blood pressure fall and metabolic syndrome score in hypertensive patients. Blood Press Monit. 2007; 12: 351-356.